Spun out of the University of Wisconsin-Madison, Imbed Biosciences Inc, is a medical device company developing advanced materials for wound healing and surgical applications based on its patent-pending nanotechnologies. Coming out of several years of research by a multidisciplinary group of engineers, veterinary scientists and medical surgeons, Imbed's founders bring to the table decades of experience in clinical wound management. By leveraging its novel biomaterials platforms, Imbed is set up to have major impact on wound dressings to prevent wound infections, expedite wound closure, and ideally reduce the overall cost of managing surgical and chronic wounds. Working on advanced therapies for the treatment of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair, the company has a portfolio of products in development based on its patented MicroLyte® Matrix technology that presents bioactive molecules on tissue surfaces to combat local pain and infections. The microscale matrix accelerates cell migration and reduces antibiotic/opioid abuse. The company is registered with U.S. FDA as a medical device manufacturer and maintains an ISO 13485 certified Quality Management System.